文献速递胸部肿瘤

阿替利珠单抗联合或不联合贝伐珠单抗及铂类-培美曲塞治疗靶向治疗后进展的EGFR突变、ALK重排或ROS1融合的IIIB/IV期非鳞状非小细胞肺癌:多中心II期开放标签非随机研究GFPC 06-2018

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.
PubMed 文献 · Eur J Cancer · 2023-01-31

本研究为法国多中心开放标签非随机非比较II期研究,纳入靶向治疗后进展的EGFR突变或ALK/ROS1融合的IIIB/IV期非鳞状非小细胞肺癌患者,接受阿替利珠单抗联合或不联合贝伐珠单抗及铂类-培美曲塞治疗。PPAB组12周客观缓解率为58.2%(90%CI 47.4-68.4),PPA组为46.5%(90%CI 36.3-56.9)。结论认为该联合方案在靶向治疗失败后取得有前景的疗效,安全性可接受。

要点

  • PPAB组12周客观缓解率58.2%(90%CI 47.4-68.4),PPA组46.5%(90%CI 36.3-56.9)。
  • PPAB组中位无进展生存期7.3个月,PPA组7.2个月;中位总生存期分别为17.2个月和16.8个月。
  • PPAB组3-4级不良事件发生率69.1%,PPA组51.4%;阿替利珠单抗相关3-4级不良事件分别为27.9%和15.3%。

核心结论

  • 阿替利珠单抗联合或不联合贝伐珠单抗及铂类-培美曲塞在酪氨酸激酶抑制剂治疗失败的转移性EGFR突变或ALK/ROS1重排NSCLC中取得有前景的活性,安全性可接受。

研究设计与样本

  • 法国国家多中心开放标签非随机非比较II期研究,纳入IIIB/IV期NSCLC、EGFR突变或ALK/ROS1融合、酪氨酸激酶抑制剂治疗后进展且未接受过化疗的患者。
  • PPAB队列71例,PPA队列78例;PPAB队列接受铂类、培美曲塞、阿替利珠单抗和贝伐珠单抗,不适合贝伐珠单抗者进入PPA队列接受铂类-培美曲塞-阿替利珠单抗。
  • 主要终点为12周后由盲法独立中心审查评估的客观缓解率(RECIST v1.1)。

主要发现

  • PPAB组平均年龄60.4岁,女性69.0%,EGFR突变87.3%,ALK重排12.7%,ROS1融合0%;PPA组平均年龄66.1岁,女性51.3%,EGFR突变89.7%,ALK重排5.1%,ROS1融合6.4%。
  • 12周客观缓解率:PPAB组58.2%(90%CI 47.4-68.4),PPA组46.5%(90%CI 36.3-56.9)。
  • 中位无进展生存期:PPAB组7.3个月(95%CI 6.9-9.0),PPA组7.2个月(95%CI 5.7-9.2);中位总生存期:PPAB组17.2个月(95%CI 13.7-NA),PPA组16.8个月(95%CI 13.5-NA)。
  • 3-4级不良事件发生率:PPAB组69.1%,PPA组51.4%;阿替利珠单抗相关3-4级不良事件发生率:PPAB组27.9%,PPA组15.3%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous reports showed limited efficacy of immune checkpoint inhibitors as single-agent treatment for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation or ALK/ROS1 fusion. We aimed at evaluating the efficacy and safety of immune checkpoint inhibitor combined with chemotherapy and bevacizumab (when eligible) in this patient subgroup. METHODS: We conducted a French national open-label multicentre non-randomised non-comparative phase II study in patients with stage IIIB/IV NSCLC, oncogenic addiction (EGFR mutation or ALK/ROS1 fusion), with disease progression after tyrosine kinase inhibitor and no prior chemotherapy. Patients received platinum, pemetrexed, atezolizumab, bevacizumab (PPAB cohort) or, if not eligible to bevacizumab, platinum-pemetrexed-atezolizumab (PPA cohort). The primary end-point was the objective response rate (RECIST v1.1) after 12 weeks, evaluated by blind independent central review. RESULTS: 71 patients were included in PPAB cohort and 78 in PPA cohort (mean age, 60.4/66.1 years; women 69.0%/51.3%; EGFR mutation, 87.3%/89.7%; ALK rearrangement, 12.7%/5.1%; ROS1 fusion, 0%/6.4%, respectively). After 12 weeks, objective response rate was 58.2% (90% confidence interval [CI], 47.4-68.4) in PPAB cohort and 46.5% (90% CI, 36.3-56.9) in PPA cohort. Median progression-free survival and overall survival were 7.3 (95% CI 6.9-9.0) months and 17.2 (95% CI 13.7-NA) months in PPAB cohort and 7.2 (95% CI 5.7-9.2) months and 16.8 (95% CI 13.5-NA) months in PPA cohort, respectively. Grade 3-4 adverse events occurred in 69.1% of patients in PPAB cohort and 51.4% in PPA cohort; Grade 3-4 atezolizumab-related adverse events occurred in 27.9% and 15.3%, respectively. CONCLUSION: Combination approach with atezolizumab with or without bevacizumab and platinum-pemetrexed achieved promising activity in metastatic EGFR-mutated or ALK/ROS1-rearranged NSCLC after tyrosine kinase inhibitor failure, with acceptable safety profile.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bylicki O, Tomasini P, Radj G, et al. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. Eur J Cancer. 2023. PMID: 36801605. doi:10.1016/j.ejca.2023.01.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。